Our Pipeline

Table of stalicla pipeline.
ASD = Autism Spectrum Disorder NAM = Negative Allosteric Modulator

STP1

STP1 is a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) shown to be a top drug match for a subgroup of patients with autism spectrum disorder (ASD) called phenotype 1.

STP1 has completed phase 1b trials showing strong safety and tolerability, improvements in brain function for executive function and memory and improved autism severity scores. STP1 is being progressed into Phase 2 trials in 2025.

STP2

STP2, or SFX-01, is a stabilized synthetic form of sulforaphane for which STALICLA has acquired the rights for neurodevelopment disorders worldwide from TheraCryf (formerly known as Evgen Pharma) in October 2022.

STP2 is being advanced as a precision medicine treatment candidate for a subgroup of patients with ASD called Phenotype 2. Phase 1 data is currently being evaluated to support further clinical development into phase 2 trials.